bFGF treatment can effectively reduce serum glucose and lipid levels in STZ-induced diabetic rats and prevent DN through inhibition of inflammation (Lin et al., 2016; Sheng et al., 2018). The gene discussed is FGF2; the disease is liver dysplastic nodule.